FGF8 Antibody

Overview

FGF8 Antibody is a research-use-only Rabbit polyclonal (rabbit origin) Rabbit IgG directed against FGF8. It is supplied for interpretation-focused detection and comparative profiling in WB, Direct ELISA. Reported localization context: Secreted.

Key elements and design rationale

• Target context: This antibody is raised against A recombinant human protein corresponding to amino acids Q23-R233 was used as the immunogen for the FGF8 antibody.. Epitope context matters because isoforms, processing, and post-translational modifications can change what is accessible in a given assay.
• Format: Antigen affinity purified. Format influences background and compatibility with different detection chemistries; conjugated formats (when present) can simplify multiplexing and reduce reliance on secondary reagents.
• Species reactivity: Human, Mouse, Rat. Cross-species performance can vary with sequence divergence and epitope conservation, so interpretation should be anchored with appropriate biological controls.
• Localization: Secreted. Subcellular compartment context can help guide expectations in imaging assays and informs fractionation-based comparisons in lysate workflows.
• Applications: WB, Direct ELISA. These indicate assay contexts where the antibody is commonly applied; actual performance depends on sample type and processing.

Polyclonal reagents can differ in how they recognize epitope features. Monoclonal antibodies often provide more consistent epitope targeting across lots, while polyclonal preparations may broaden recognition across related epitope variants.

Biological background

FGF8 refers to the gene/protein target stated in the product record. Protein targets can exhibit context-dependent expression, regulated turnover, isoform diversity, and post-translational modifications that affect apparent molecular weight and epitope accessibility. For curated functional annotation, sequence features, and expression context, consult UniProtKB P55075, Ensembl, and Human Protein Atlas.

Research relevance and current trends

• Integrating antibody-based detection with single-cell and spatial atlasing efforts to connect RNA programs with protein-level abundance and localization in defined cell states.
• Expanding multiplexed imaging and high-content screening, where reagent specificity, cross-reactivity risk, and channel design (including direct conjugates) become central to interpretation.
• Growing emphasis on reproducibility and application-specific validation frameworks (e.g., genetic perturbation controls, orthogonal measurements, and independent antibody strategies) when drawing mechanistic conclusions.

Common research applications

• Western blot (WB): commonly used to compare relative abundance/size (e.g., band intensity or mobility shifts) between conditions.
• Direct ELISA: commonly used for qualitative/quantitative detection where compatible with the assay context.

Interpretation typically focuses on relative differences (presence/absence, fold-changes, compartment shifts, or population-level shifts) rather than absolute quantitation. When signal changes are observed, they may reflect altered expression, altered localization/trafficking, changes in modification state, or differences in sample composition; orthogonal readouts and appropriate controls help distinguish these possibilities.

Application details (record-specific): Western Blot: 0.5-1ug/ml,Direct ELISA (recombinant human protein): 0.1-0.5ug/ml (BSA-free format available)

Application notes (record-specific): Optimal dilution of the FGF8 antibody should be determined by the researcher.

Notes for experimental interpretation

• Product description (record-specific): Fibroblast growth factor 8 (androgen-induced), also known as FGF8 or AIGF, is a human gene which maps to 10q24. The protein encoded by this gene is secreted proteins that interact with FGF tyrosine kinase receptors to mediate growth and development. This protein is known to be a factor that supports androgen and anchorage independent growth of mammary tumor cells. Overexpression of this gene has been shown to increase tumor growth and angiogensis. The temporal and spatial patterns of this gene expression suggest that FGF8 is involved in gastrulation, regionalization of the brain, and organogenesis of the limb and face as an embryonic epithelial factor. The adult expression of FGF8 is restricted to gonads, including testes and ovaries. FGF8 stimulated growth of human prostate carcinoma cells and mouse fibroblasts and mammary carcinoma cells in a dose-dependent manner. It also may play an important role in growth and patterning of limbs, face, and central nervous system. FGF8 is expressed in increased levels in breast cancer and in lactating human breast; it was also detected in human milk. A survey of other normal tissues showed that FGF8 is expressed in the proliferative cells of the skin and epithelial cells in colon, ovary, fallopian tube, and uterus.
• Potential confounders: isoforms, proteolytic processing, and PTMs can change epitope presentation and apparent size; fixation/denaturation state can also expose or mask epitopes. Species differences near the epitope may affect cross-reactivity.
• Control concepts: include genetic perturbation (KO/KD) or overexpression comparisons, orthogonal measurement (e.g., transcript or proteomics), and independent antibody/epitope strategies. For conjugated reagents, include staining-only/background controls appropriate to the detection chemistry.

Immunogen/epitope context is described as: A recombinant human protein corresponding to amino acids Q23-R233 was used as the immunogen for the FGF8 antibody.. Monoclonal and polyclonal formats differ in epitope breadth; this can influence sensitivity to sequence variants, isoforms, or PTM-dependent recognition.

• Datasheet (FGF8-ANTIBODY-R32870)

Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.